Diagnostics

Pearl’s new FDA-cleared 3D imaging AI is set to democratize advanced diagnostics, empowering general dentists to see more and reshaping patient care.

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.

Life Line Screening's p-tau217 test democratizes Alzheimer's risk assessment, raising critical questions about non-diagnostic data and patient well-being.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

As Alamar Biosciences prepares for a key fireside chat at Morgan Stanley, all eyes are on its NULISA™ technology and its rapid commercial growth.

Israeli firm Medibyt's FDA-cleared AI platform, CPETWise, slashes diagnostic time by over 50%, promising to make complex heart and lung tests more accessible.

A new public-private alliance aims to fast-track critical diagnostics and medical devices, bridging the gap between innovation and emergency preparedness.

Fujirebio's new Health Canada-approved assays promise a new era for brain health diagnostics, but questions of patient access and cost loom large.

A $10M federal contract aims to slash the 7-year wait for rare disease diagnoses. Discover how Probably Genetic's AI and direct-to-patient data are leading the charge.

As its CFO prepares for a key conference, Bio-Rad is navigating a major restructuring, activist pressure, and a divided market performance. What will he say?

As Labcorp executives prepare for a key fireside chat, investors and industry watchers anticipate insights into AI, personalized medicine, and future growth.

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

A new partnership merges genetic screening and sperm analysis, promising empowered family planning. But as data deepens, are we crossing an ethical frontier?

A new blood test can predict preterm birth risk months in advance, shifting prenatal care from reactive crisis to proactive strategy and saving billions.

As Lumexa Imaging execs hit the road for a four-conference tour, is it a victory lap for recent profits or a strategic play to manage debt and woo investors?

Quest Diagnostics is bringing longevity science to the masses with a new biological age test. Sandra Patterson explores the investment and ethical calculus.

New studies show AI can quantify subtle lung damage, offering hope for earlier, more personalized treatment of Interstitial Lung Disease. What does this mean?

From stroke pioneer to lung disease disruptor, Brainomix's new AI studies signal a major shift in diagnostics. This is the story behind the numbers.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.